Education
About Us
Working with TipRanks
Follow Us
Verastem (VSTM)
NASDAQ:VSTM
Cetuximab, Vs-7375
Colorectal Cancer, Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Adult, G12d Mutated Kras
Phase I/II
Recruiting
A Phase 1/2a Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
May 26, 2025
―
Avutometinib (Vs-6766) + Defactinib (Vs-6063)
Ovarian Cancer, Low Grade Serous Ovarian Cancer
Phase II
Recruiting
A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
Nov 05, 2024
―
Avutometinib (Vs-6766) And Defactinib In Combination With Gemcitabine And Nab-Paclitaxel
Metastatic Cancer, Pancreas Cancer, Kras Activating Mutation, Neoplasms Pancreatic, Malignant Neoplasm Of Pancreas
Phase I/II
Active Not Recruiting
Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
Dec 06, 2022
―
Avutometinib (Vs-6766) And Adagrasib
Non Small Cell Lung Cancer, Advanced Cancer, Metastatic Cancer, Kras Activating Mutation, Malignant Neoplastic Disease, Malignant Neoplasm Of Lung
Phase I/II
Active Not Recruiting
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
May 02, 2022
―
Vs-6766
Food Effect
Phase I
Completed
Food Effect of VS-6766 in Healthy Adult Subjects
Dec 23, 2021
―
Avutometinib And Sotorasib, Avutometinib And Sotorasib And Defactinib
Non Small Cell Lung Cancer, Kras Activating Mutation
Phase I/II
Recruiting
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Sep 29, 2021
―
Avutometinib (Vs-6766), Avutometinib (Vs-6766) And Defactinib
Non Small Cell Lung Cancer, Kras Activating Mutation
Phase II
Completed
A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Nov 05, 2020
―
Avutometinib (Vs-6766), Avutometinib (Vs-6766) And Defactinib
Ovarian Cancer, Low Grade Ovarian Serous Adenocarcinoma
Phase II
Active Not Recruiting
A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation
Nov 05, 2020
―
Part A - Vs-6063, Part A - Avelumab
Epithelial Ovarian Cancer
Phase I
Terminated
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
Oct 17, 2016
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Verastem (VSTM) have in its pipeline
VSTM is currently developing the following drugs: Cetuximab, Vs-7375, Avutometinib (Vs-6766) + Defactinib (Vs-6063), Paclitaxel, Avutometinib, Defactinib, Pegylated Liposomal Doxorubicin, Letrozole, Anastrozole. These drug candidates are in various stages of clinical development as the company works toward FDA approval.